ESCR
MCID: ESP021
MIFTS: 82

Esophageal Cancer (ESCR)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Esophageal Cancer

MalaCards integrated aliases for Esophageal Cancer:

Name: Esophageal Cancer 58 39 12 54 76 38 13 44 15
Esophageal Carcinoma 12 56 15 17 74
Esophageal Squamous Cell Carcinoma 60 76 6 17
Esophageal Squamous Cell Carcinoma, Somatic 58 6
Esophageal Carcinoma, Somatic 58 6
Gastric Cardia Adenocarcinoma 76 74
Carcinoma of Esophagus 12 6
Esophageal Neoplasms 45 74
Esophagus Cancer 12 54
Escc 60 76
Malignant Tumor of the Middle Third of the Esophagus 12
Malignant Neoplasm of Proximal Third of Esophagus 12
Malignant Neoplasm of Middle Third of Oesophagus 12
Malignant Neoplasm of Distal Third of Esophagus 12
Malignant Neoplasm of Lower Third of Oesophagus 12
Malignant Neoplasm of Middle Third of Esophagus 74
Malignant Tumor of Proximal Third of Esophagus 12
Malignant Tumor of Distal Third of Esophagus 12
Malignant Neoplasm of Upper Third Esophagus 12
Squamous Cell Carcinoma of the Esophagus 60
Malignant Tumor of Abdominal Esophagus 12
Squamous Cell Carcinoma of Esophagus 74
Esophageal Epidermoid Carcinoma 60
Squamous Cell Esophageal Cancer 56
Malignant Neoplasm of Esophagus 74
Esophageal Cancer, Somatic 58
Ca Middle Third Oesophagus 12
Aerodigestive Tract Cancer 76
Ca Lower Third Oesophagus 12
Carcinoma of Oesophagus 12
Cancer of Oesophagus 12
Cancer of Esophagus 12
Cancer, Esophageal 41
Escr 76

Characteristics:

Orphanet epidemiological data:

60
squamous cell carcinoma of the esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Adult; Age of death: adult;

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation


HPO:

33
esophageal cancer:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



Summaries for Esophageal Cancer

NIH Rare Diseases : 54 Esophageal cancer is a cancer of the esophagus, the hollow tube that carries foods and liquids from the throat to the stomach. Symptoms that may develop as the cancer grows include heartburn, pain when swallowing, difficulty swallowing, a hoarse voice, a cough that does not go away, weight loss, and coughing up blood. The exact cause of esophageal cancer usually is not known, but both environmental and genetic factors are thought to play a role in its development. For example, variations or mutations in any of several genes may cause susceptibility to esophageal cancer.Environmental factors that may increase a person's chance to develop esophageal cancer include tobacco use, heavy alcohol use, older age, obesity, and damage to the esophagus from acid reflux (Barrett esophagus). The diagnosis may be based on imaging studies and tests such as chest X-ray, upper endoscopy, and a biopsy of tissue from the esophagus. Treatment options and the chance of recovery depend on the stage of the cancer, whether it can be surgically removed, and a person's general health. Treatment options may include surgery, radiation therapy, chemotherapy, laser therapy, and electrocoagulation. Other treatment options, such as targeted therapy, are being studied in clinical trials. When it is found very early, there is a better chance of recovery. When the cancer is more advanced, it can be treated but rarely can be cured.

MalaCards based summary : Esophageal Cancer, also known as esophageal carcinoma, is related to adenocarcinoma and esophageal basaloid squamous cell carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Esophageal Cancer is TGFBR2 (Transforming Growth Factor Beta Receptor 2), and among its related pathways/superpathways are MicroRNAs in cancer and Activation of cAMP-Dependent PKA. The drugs Actiq and Adcetris have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and breast, and related phenotypes are feeding difficulties in infancy and esophageal carcinoma

Disease Ontology : 12 A gastrointestinal system cancer that is located in the esophagus.

OMIM : 58 Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most common cancers worldwide. Both environmental and genetic risk factors play a role in the pathogenesis of the disorder. In Europe and North America, heavy smoking, alcohol consumption, and increased body mass index (BMI) are the main environmental risk factors. In contrast, the particularly high incidence of ESCC in some areas of China, central Asia, and southern Africa is associated with nutritional deficiencies, high intake of nitrosamine-rich or pickled vegetables, and low socioeconomic status; smoking, alcohol consumption, and BMI play a lesser role in these populations. There is a tendency for familial aggregation of ESCC in high-risk geographic areas, suggesting a genetic component to increased susceptibility. Gastric cardia adenocarcinoma is another common type of cancer in China that shows similarities to ESCC in terms of geographic distribution and environmental risk factors (summary by Wang et al., 2010 and Abnet et al., 2010). (133239)

MedlinePlus : 44 The esophagus is a hollow tube that carries food and liquids from your throat to your stomach. Early esophageal cancer usually does not cause symptoms. Later, you may have symptoms such as Painful or difficult swallowing Weight loss A hoarse voice or cough that doesn't go away You're at greater risk for getting esophageal cancer if you smoke, drink heavily, or have acid reflux. Your risk also goes up as you age Your doctor uses imaging tests and a biopsy to diagnose esophageal cancer. Treatments include surgery, radiation, and chemotherapy. You might also need nutritional support, since the cancer or treatment may make it hard to swallow. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 76 Esophageal cancer: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.

Wikipedia : 77 Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Related Diseases for Esophageal Cancer

Diseases related to Esophageal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 464)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 33.3 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
2 esophageal basaloid squamous cell carcinoma 33.0 CTNNB1 EGFR TP53 WWOX
3 squamous cell carcinoma 31.8 CTNNB1 EGFR ERBB2 HRAS LZTS1 PIK3CA
4 gastric cancer 31.7 CTNNB1 EGFR ERBB2 KRAS MIR21 MIR34A
5 gastric adenocarcinoma 31.5 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
6 lung cancer 31.4 EGFR ERBB2 HRAS KRAS MIR126 MIR148A
7 breast cancer 31.3 CTNNB1 EGFR ERBB2 HRAS KRAS MIR126
8 barrett's adenocarcinoma 31.2 ERBB2 KRAS TP53
9 hepatocellular carcinoma 31.1 CTNNB1 EGFR HRAS KRAS MIR126 MIR148A
10 colorectal cancer 31.1 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
11 pancreatic cancer 31.0 CTNNB1 EGFR ERBB2 HRAS KRAS MIR148A
12 ovarian cancer 31.0 CTNNB1 EGFR ERBB2 KRAS MIR126 MIR21
13 glioma 31.0 EGFR ERBB2 MIR21 MIR34A PIK3CA TP53
14 esophageal disease 31.0 EGFR ERBB2 TP53 WWOX
15 small cell cancer of the lung 30.9 EGFR MIR21 PIK3CA TP53
16 esophagus adenocarcinoma 30.8 ERBB2 MIR21 SMAD4 TP53
17 bladder cancer 30.8 EGFR ERBB2 HRAS KRAS MIR21 TP53
18 adenoid cystic carcinoma 30.8 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
19 oral cancer 30.8 EGFR MIR21 TP53
20 ovarian cancer 1 30.7 ERBB2 KRAS PIK3CA TP53
21 prostate cancer 30.7 CTNNB1 EGFR ERBB2 HRAS KRAS MIR126
22 carcinosarcoma 30.7 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
23 colorectal adenocarcinoma 30.6 CTNNB1 EGFR HRAS KRAS TP53
24 lung cancer susceptibility 3 30.6 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
25 sarcoma 30.6 CTNNB1 HRAS KRAS PIK3CA TP53
26 in situ carcinoma 30.6 EGFR ERBB2 TP53
27 adenoma 30.6 CTNNB1 KRAS SMAD4 TGFBR2 TP53
28 pancreas adenocarcinoma 30.6 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
29 thyroid cancer 30.6 CTNNB1 EGFR HRAS KRAS PIK3CA TP53
30 squamous cell carcinoma, head and neck 30.6 CTNNB1 EGFR ERBB2 HRAS MIR148A MIR21
31 cervical cancer 30.6 CTNNB1 ERBB2 HRAS MIR21 PIK3CA SMAD4
32 leukemia, chronic lymphocytic 2 30.6 HRAS KRAS MIR34A TP53
33 large intestine cancer 30.5 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
34 familial adenomatous polyposis 30.5 CTNNB1 KRAS SMAD4 TP53
35 kidney cancer 29.9 MIR126 MIR21 TP53
36 tylosis with esophageal cancer 12.7
37 gastric cardia adenocarcinoma 12.7
38 esophageal cancer, childhood 12.2
39 mucoepidermoid esophageal carcinoma 12.1
40 esophagus small cell carcinoma 11.5
41 esophagus verrucous carcinoma 11.1
42 esophagus squamous cell carcinoma 11.1
43 esophageal adenoid cystic carcinoma 11.1
44 esophageal adenosquamous carcinoma 11.1
45 carcinoma of esophagus, salivary gland type 11.1
46 undifferentiated carcinoma of esophagus 11.1
47 palmoplantar keratoderma, epidermolytic 11.1
48 esophagus sarcoma 11.1
49 stomach disease 10.9 CTNNB1 EGFR ERBB2 TP53 WWOX
50 adamantinoma of long bones 10.9 CTNNB1 EGFR ERBB2 KRAS PIK3CA TP53

Comorbidity relations with Esophageal Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Deficiency Anemia
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Heart Disease
Neutropenia Protein-Energy Malnutrition
Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Cancer:



Diseases related to Esophageal Cancer

Symptoms & Phenotypes for Esophageal Cancer

Human phenotypes related to Esophageal Cancer:

60 33 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 feeding difficulties in infancy 60 33 hallmark (90%) Very frequent (99-80%) HP:0008872
2 esophageal carcinoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0011459
3 clinodactyly of the 5th toe 60 33 hallmark (90%) Very frequent (99-80%) HP:0001864
4 dysphagia 33 hallmark (90%) HP:0002015
5 weight loss 33 hallmark (90%) HP:0001824
6 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
7 abnormality of the voice 60 33 frequent (33%) Frequent (79-30%) HP:0001608
8 chest pain 60 33 frequent (33%) Frequent (79-30%) HP:0100749
9 cough 60 33 frequent (33%) Frequent (79-30%) HP:0012735
10 lymphadenopathy 60 33 frequent (33%) Occasional (29-5%) HP:0002716
11 recurrent singultus 33 frequent (33%) HP:0100247
12 gastroesophageal reflux 33 frequent (33%) HP:0002020
13 abnormality of the neck 33 frequent (33%) HP:0000464
14 obesity 33 occasional (7.5%) HP:0001513
15 barrett esophagus 33 occasional (7.5%) HP:0100580
16 abnormal intestine morphology 33 occasional (7.5%) HP:0002242
17 squamous cell carcinoma 33 HP:0002860

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
esophageal cancer
esophageal squamous cell carcinoma

Clinical features from OMIM:

133239

UMLS symptoms related to Esophageal Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, tinnitus, snoring, sore throat, icterus, coughing, vertigo/dizziness, equilibration disorder, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Esophageal Cancer according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.69 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.69 KRAS
3 Decreased viability GR00107-A-1 10.69 TGFBR2
4 Decreased viability GR00221-A-1 10.69 EGFR HRAS KRAS PIK3CA TGFBR2
5 Decreased viability GR00221-A-2 10.69 HRAS KRAS PIK3CA DCC
6 Decreased viability GR00221-A-3 10.69 HRAS TGFBR2 DCC ERBB2
7 Decreased viability GR00221-A-4 10.69 EGFR PIK3CA TGFBR2 DCC ERBB2
8 Decreased viability GR00301-A 10.69 KRAS
9 Decreased viability GR00381-A-1 10.69 KRAS
10 Decreased viability GR00402-S-2 10.69 EGFR HRAS KRAS PIK3CA TGFBR2 DCC
11 Decreased cell migration GR00055-A-1 9.65 CTNNB1 EGFR HRAS KRAS PIK3CA
12 Increased cell death HMECs cells GR00103-A-0 9.43 CTNNB1 EGFR PIK3CA TGFBR2 TP53 WWOX
13 Increased cell migration GR00055-A-3 9.02 CTNNB1 EGFR HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Esophageal Cancer:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.28 CTNNB1 DCC EGFR ERBB2 KRAS LZTS1
2 endocrine/exocrine gland MP:0005379 10.18 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
3 digestive/alimentary MP:0005381 10.16 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
4 neoplasm MP:0002006 10.15 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
5 craniofacial MP:0005382 10.13 CTNNB1 EGFR ERBB2 HRAS KRAS SMAD4
6 embryo MP:0005380 10.1 CTNNB1 EGFR ERBB2 KRAS PIK3CA SMAD4
7 nervous system MP:0003631 10.1 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
8 integument MP:0010771 10.06 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
9 muscle MP:0005369 10.01 CTNNB1 EGFR ERBB2 KRAS PIK3CA SMAD4
10 liver/biliary system MP:0005370 9.98 CTNNB1 EGFR KRAS SMAD4 TGFBR2 TP53
11 no phenotypic analysis MP:0003012 9.8 CTNNB1 EGFR HRAS KRAS PIK3CA TP53
12 respiratory system MP:0005388 9.56 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
13 pigmentation MP:0001186 9.55 CTNNB1 DCC EGFR KRAS TP53
14 skeleton MP:0005390 9.32 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA

Drugs & Therapeutics for Esophageal Cancer

FDA approved drugs:

(show top 50) (show all 71)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Actiq 19 FENTANYL (citrate) Anesta Corporation November 1998
2
Adcetris 19 50 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
3
Aromasin Tablets 19 50 EXEMESTANE Pharmacia & Upjohn October 21. 1999
4
Beleodaq 19 50 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Farydak 19 50 PANOBINOSTAT LACTATE Novartis February 2015
6
Faslodex 19 50 FULVESTRANT AstraZeneca April 2002
7
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
8
Gleevec 19 50 IMATINIB MESYLATE Novartis May 2001
9
Ibrance 19 50 PALBOCICLIB Pfizer February 2015
10
Inlyta 19 50 AXITINIB Pfizer January 2012
11
Intron A 19 50 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
12
Keytruda 19 50 PEMBROLIZUMAB Merck September 2014
13
Lynparza 19 50 OLAPARIB AstraZeneca December 2014
14
Nolvadex 19 50 TAMOXIFEN CITRATE AstraZeneca October 1998
15
Opdivo 19 50 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
16
Photodynamic Therapy (& Photofrin) 19 PORFIMER SODIUM Sanofi-aventis January, 1996
17
Photofrin 19 PORFIMER SODIUM QLT January 1998
18
Zevalin 19 50 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
19
Zometa 19 50 ZOLEDRONIC ACID Novartis August 2001/ February 2002
20
Zykadia 19 50 CERITINIB Novartis April 2014
21
Advair 19 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
22
Alecensa 19 ALECTINIB HYDROCHLORIDE Roche December 2015
23
Allegra 19 FEXOFENADINE HYDROCHLORIDE Hoechst Marion Roussel July 1996
24
Allegra-D 19 FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE Hoechst Marion Roussel March 1998
25
Augmentin 19 AMOXICILLIN; CLAVULANATE POTASSIUM SmithKline Beecham February 1996
26
Azmacort 19 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
27
Breathe Right 19 CNS June 1996
28
Cafcit Injection 19 CAFFEINE CITRATE Roxane Laboratories September 1999
29
Cedax 19 CEFTIBUTEN DIHYDRATE Schering-Plough December 1995
30
Cefazolin and Dextrose USP 19 CEFAZOLIN SODIUM B Braun Medical July 2000
31
Claritin RediTabs 19 LORATADINE Schering-Plough January 1997
32
Claritin-D 24 Hour Extended Release Tablets 19 LORATADINE; PSEUDOEPHEDRINE SULFATE Schering-Plough August 1996
33
Covera-HS 19 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996
34
Daliresp 19 ROFLUMILAST Forest Pharmaceuticals February 2011
35
Dulera 19 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
36
DuoNeb 19 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
37
Esbriet 19 PIRFENIDONE InterMune October 2014
38
Foradil Aerolizer 19 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
39
Grastek 19 Timothy Grass Pollen Allergen Extract Merck April 2014
40
Iressa 19 GEFITINIB AstraZeneca May 2003
41
Kalydeco 19 IVACAFTOR Vertex Pharmaceuticals January of 2012
42
Letairis 19 AMBRISENTAN Gilead June 2007
43
Nucala 19 MEPOLIZUMAB GlaxoSmithKline November 2015
44
Orkambi 19 IVACAFTOR; LUMACAFTOR Vertex Pharmaceuticals July 2015
45
Patanase 19 OLOPATADINE HYDROCHLORIDE Alcon April 2008
46
Portazza 19 NECITUMUMAB Eli Lilly November 2015
47
Priftin 19 RIFAPENTINE Hoechst Marion Roussel June 1998
48
Pulmozyme 19 DORNASE ALFA Genentech December 1996|March 1998
49
Qvar 19 BECLOMETHASONE DIPROPIONATE Ivax May 2002
50
Ragwitek 19 Merck April 2014

Drugs for Esophageal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 549)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
3
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
4
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
5
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-78-2 2244
8
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
9
Iron Approved, Experimental Phase 4,Phase 1 7439-89-6, 15438-31-0 27284 23925
10
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
11
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
12
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
13
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
14
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
15
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
16
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
17
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
18
Norepinephrine Approved Phase 4 51-41-2 439260
19
Dobutamine Approved Phase 4 34368-04-2 36811
20
Phenylephrine Approved Phase 4 59-42-7 6041
21
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
22
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
23
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
27
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
28
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
29
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
30
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 7440-70-2 271
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
32
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
33 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Anticholesteremic Agents Phase 4
35 Lipid Regulating Agents Phase 4,Phase 1
36 Hypolipidemic Agents Phase 4,Phase 1
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
38 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Omega 3 Fatty Acid Phase 4,Phase 2
41 Epinephryl borate Phase 4,Phase 2,Not Applicable
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Ferric Compounds Phase 4
48 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Nutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1460)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
3 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
4 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
5 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX Unknown status NCT02609425 Phase 4
6 Postoperative Pain Management After Minimally Invasive Esophagectomy Unknown status NCT02042313 Phase 4
7 Radiofrequency in the Treatment of Barrett's Oesophagus Unknown status NCT02558504 Phase 4
8 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
9 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
10 Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer Completed NCT00911092 Phase 4 Chemotherapy (Fluorouracil and Cisplatin)
11 Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma Not yet recruiting NCT03413436 Phase 4 Lobaplatin;Cisplatin
12 INEC Study: Immuno-modulating Enteral Nutrition in Cancer Completed NCT00333099 Phase 4
13 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection Completed NCT01416077 Phase 4
14 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
15 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
16 Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Completed NCT02320734 Phase 4 Rocuronium
17 HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery Enrolling by invitation NCT03642093 Phase 4
18 The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I Recruiting NCT02845479 Phase 4
19 The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery Completed NCT02439905 Phase 4 Dexmedetomidine;Placebo control
20 Barretts oEsophageal Resection With Steroid Therapy Trial Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
21 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
22 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
23 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
24 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
25 Low-dose Aspirin Therapy for Esophageal Cancer Unknown status NCT02326779 Phase 3 Acetylsalicylic acid
26 Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer Unknown status NCT02355249 Phase 3
27 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
28 a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent Unknown status NCT01054274 Phase 3
29 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
30 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
31 Comparable Study of Different Radiation Dose in Esophageal Carcinoma Unknown status NCT01937208 Phase 3 concurrent chemotherapy with radiation
32 Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer Unknown status NCT00686114 Phase 3 Paclitaxel;Cisplatin;Tarceva
33 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma Unknown status NCT01034683 Phase 3 lobaplatin , 5-FU ,leucovorin
34 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
35 Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches Unknown status NCT01053182 Phase 3
36 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
37 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
38 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
39 Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy Unknown status NCT01242124 Phase 2, Phase 3
40 Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial Unknown status NCT00193817 Phase 3
41 The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy Unknown status NCT01361750 Phase 3
42 Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial Unknown status NCT02780921 Phase 3
43 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
44 Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers Unknown status NCT01911832 Phase 3
45 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Unknown status NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
46 Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer Unknown status NCT02375997 Phase 3
47 Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer Unknown status NCT01786278 Phase 2, Phase 3
48 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
49 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
50 A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer Not yet recruiting NCT03708042 Phase 3

Search NIH Clinical Center for Esophageal Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Esophageal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Esophageal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Esophageal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: esophageal neoplasms

Genetic Tests for Esophageal Cancer

Anatomical Context for Esophageal Cancer

MalaCards organs/tissues related to Esophageal Cancer:

42
Lung, Lymph Node, Breast, Testes, T Cells, Liver, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Esophageal Cancer:

20
The Esophagus

Publications for Esophageal Cancer

Articles related to Esophageal Cancer:

(show top 50) (show all 6790)
# Title Authors Year
1
Incidence and risk factors for esophageal cancer following achalasia treatment: national population-based case-control study. ( 30809653 )
2019
2
Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett's-associated adenocarcinoma? ( 31059738 )
2019
3
Rare pancreatic carcinosarcoma in a patient with medical history of esophageal cancer: A case report and literature review. ( 31008956 )
2019
4
Factors associated with overall survival and relief of dysphagia in advanced esophageal cancer patients after 125I seed-loaded stent placement: a multicenter retrospective analysis. ( 30888392 )
2019
5
Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial. ( 30084992 )
2019
6
Long-term pharyngeal dysphagia after esophagectomy for esophageal cancer-an investigation using videofluoroscopic swallow studies. ( 30085000 )
2019
7
Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer. ( 31040700 )
2019
8
Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. ( 31043861 )
2019
9
The emerging role of immunotherapy for esophageal cancer. ( 31045596 )
2019
10
A population-based survey of gastroesophageal reflux disease in regions of high prevalence of esophageal cancer in china. ( 31045906 )
2019
11
Multidisciplinary Therapy of Esophageal Cancer. ( 31047033 )
2019
12
What Is the Best Operation for Proximal Gastric Cancer and Distal Esophageal Cancer? ( 31047035 )
2019
13
Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West. ( 31047037 )
2019
14
Managing Squamous Cell Esophageal Cancer. ( 31047040 )
2019
15
Palliative Management of Gastric and Esophageal Cancer. ( 31047042 )
2019
16
Prehabilitation for Patients With Esophageal Cancer During Neoadjuvant Treatment and Surgery. ( 31059943 )
2019
17
Response to "Prehabilitation for Patients With Esophageal Cancer During Neoadjuvant Treatment and Surgery". ( 31059946 )
2019
18
Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer. ( 31064964 )
2019
19
Efficacy of Endoscopic Evaluation of Acute Radiation Esophagitis during Chemoradiotherapy with Proton Beam Therapy Boost for Esophageal Cancer. ( 31067539 )
2019
20
Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence. ( 31069192 )
2019
21
FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer. ( 30863993 )
2019
22
Impact of hybrid FDG-PET/CT on gross tumor volume definition of cervical esophageal cancer: reducing interobserver variation. ( 30864652 )
2019
23
Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway. ( 30866034 )
2019
24
Prognostic significance of tumor length in patients with esophageal cancer undergoing radical resection: A PRISMA-compliant meta-analysis. ( 30946339 )
2019
25
A patient with T4 esophageal cancer cured by radical resection combined with an aortic arch aneurysm, coronary heart disease, hypertension, diabetes, and other high-risk factors. ( 30947500 )
2019
26
The National Cohort of Esophageal Cancer-Prospective Cohort Study of Esophageal Cancer and Precancerous Lesions based on High-Risk Population in China (NCEC-HRP): study protocol. ( 30948615 )
2019
27
IL-10 in vitro could enhance IFNγ expression and suppress PD-1 expression in CD8 T cells from esophageal cancer patients. ( 30951709 )
2019
28
The Association of Consumption of Animal Proteins and the Risk of Esophageal Cancer. ( 30955361 )
2019
29
Effect of lymph node examined count on accurate staging and survival of resected esophageal cancer. ( 30957414 )
2019
30
Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study. ( 30972455 )
2019
31
Differential Analysis of lncRNA, miRNA and mRNA Expression Profiles and the Prognostic Value of lncRNA in Esophageal Cancer. ( 30972633 )
2019
32
Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study. ( 30975447 )
2019
33
Innovative fully robotic 4-arm Ivor Lewis esophagectomy for esophageal cancer (RAMIE4). ( 30980079 )
2019
34
Significance of the board-certified surgeon systems and clinical practice guideline adherence to surgical treatment of esophageal cancer in Japan: a questionnaire survey of departments registered in the National Clinical Database. ( 30980202 )
2019
35
Overexpression of macrophage stimulating 1 enhances the anti-tumor effects of IL-24 in esophageal cancer via inhibiting ERK-Mfn2 signaling-dependent mitophagy. ( 30981108 )
2019
36
Hsa_circ_0004370 promotes esophageal cancer progression through miR-1294/LASP1 pathway. ( 30988074 )
2019
37
Management of intrathoracic and cervical anastomotic leakage after esophagectomy for esophageal cancer: a systematic review. ( 30988695 )
2019
38
Loss of G3BP1 suppresses proliferation, migration, and invasion of esophageal cancer cells via Wnt/β-catenin and PI3K/AKT signaling pathways. ( 30989663 )
2019
39
Correlation between the protein expression levels of A-kinase anchor protein95, p-retinoblastoma (Ser780), cyclin D2/3, and cyclin E2 in esophageal cancer tissues. ( 30990963 )
2019
40
Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer. ( 30788714 )
2019
41
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. ( 30789414 )
2019
42
Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta-analysis and genome-wide association studies. ( 30793520 )
2019
43
Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. ( 30804133 )
2019
44
Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. ( 30804146 )
2019
45
Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience. ( 30804150 )
2019
46
WISP2 exhibits its potential antitumor activity via targeting ERK and E-cadherin pathways in esophageal cancer cells. ( 30808397 )
2019
47
Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy. ( 30809782 )
2019
48
Soft-Tissue Metastases From Esophageal Cancer. ( 30809784 )
2019
49
Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial. ( 30809788 )
2019
50
Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to Open Esophagectomy: A Systematic Review and Meta-analysis. ( 30817355 )
2019

Variations for Esophageal Cancer

UniProtKB/Swiss-Prot genetic disease variations for Esophageal Cancer:

76
# Symbol AA change Variation ID SNP ID
1 TGFBR2 p.Glu526Gln VAR_015816 rs121918714

ClinVar genetic disease variations for Esophageal Cancer:

6 (show top 50) (show all 516)
# Gene Variation Type Significance SNP ID Assembly Location
1 LZTS1 NM_021020.4(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh37 Chromosome 8, 20112608: 20112608
2 LZTS1 NM_021020.4(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh38 Chromosome 8, 20255097: 20255097
3 LZTS1 NM_021020.4(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh37 Chromosome 8, 20111087: 20111087
4 LZTS1 NM_021020.4(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh38 Chromosome 8, 20253576: 20253576
5 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh37 Chromosome 16, 78466465: 78466465
6 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh38 Chromosome 16, 78432568: 78432568